Background/Aims: To clarify risk factors and clinical features of both hepatitis B surface antigen and anti-HCV negative hepatocellular carcinoma (NBNC-HCC). Methods: HCC patients (n = 1,109) diagnosed at a single center were categorized based on the presence of serum hepatitis B surface antigen and HCVAb. Clinical characteristics of 127 NBNC-HCC patients were evaluated. Results: NBNC-HCC patients were stratified as those with alcoholic liver disease (ALD-HCC, n = 42) and alcohol-unrelated liver disease (non-ALD-HCC, n = 85). Compared with the ALD-HCC group, the non-ALD-HCC group had a higher prevalence of diabetes (p = 0.015), larger tumor size (p = 0.007), and higher tumor marker levels (p = 0.014). Liver function results were significantly worse in ALD-HCC than in non-ALD-HCC. Although the ALD-HCC group had a higher tendency toward recurrence than the non-ALD-HCC group, survival rates were similar between groups (p = 0.352). Conclusion: Alcohol consumption was the most common etiologic factor for NBNC-HCC, and diabetes may be related to the development of HCC in non-ALD-HCC patients. Non-ALD-HCC tended to be diagnosed at a more advanced stage, whereas liver function was worse, and tumor recurrence rate was higher in ALD-HCC patients. Further examination of the risk factors and establishment of a precise surveillance system are necessary for early diagnosis and the development of curative therapies for NBNC-HCC.

Journal Section:
Paper
Keywords:
Liver cancer, Non-B non-C hepatocellular carcinoma, Nonalcoholic steatohepatitis, Alcohol, Diabetes
1.
El-Serag HB, Marrero JA, Rudolph L, Reddy KR: Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology 2008;134:1752–1763.
[PubMed]
https://doi.org/10.1053%2Fj.gastro.2008.02.090
2.
Kudo M, Okanoue T: Management of hepatocellular carcinoma in Japan: consensus-based clinical practice manual proposed by the Japan Society of Hepatology. Oncology 2007;72(suppl 19):2–15.
https://doi.org/10.1159%2F000111702
3.
Hatanaka K, Kudo M, Fukunaga T, Ueshima K, Chung H, Minami Y, Sakaguchi Y, Hagiwara S, Orino A, Osaki Y: Clinical characteristics of NonBNonC-HCC: Comparison with HBV and HCV related HCC. Intervirology 2007;50:24–31.
[PubMed]
https://doi.org/10.1159%2F000096309
4.
Nordenstedt H, White DL, El-Serag HB: The changing pattern of epidemiology in hepatocellular carcinoma. Dig Liver Dis 2010;42(suppl 3):S206–S214.
[PubMed]
https://doi.org/10.1016%2FS1590-8658%2810%2960507-5
5.
Nouso K, Kobayashi Y, Nakamura S, Kobayashi S, Toshimori J, Kuwaki K, Hagihara H, Onishi H, Miyake Y, Ikeda F, Shiraha H, Takaki A, Iwasaki Y, Kobashi H, Yamamoto K: Evolution of prognostic factors in hepatocellular carcinoma in Japan. Aliment Pharmacol Ther 2010;31:407–414.
[PubMed]
https://doi.org/10.1111%2Fj.1365-2036.2009.04179.x
6.
Tanaka H, Imai Y, Hiramatsu N, Ito Y, Imanaka K, Oshita M, Hijioka T, Katayama K, Yabuuchi I, Yoshihara H, Inoue A, Kato M, Takehara T, Tamura S, Kasahara A, Hayashi N, Tsukuma H: Declining incidence of hepatocellular carcinoma in Osaka, Japan, from 1990 to 2003. Ann Intern Med 2008;148:820–826.
[PubMed]
7.
Nishiguchi S, Kuroki T, Nakatani S, Morimoto H, Takeda T, Nakajima S, Shiomi S, Seki S, Kobayashi K, Otani S: Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995;346:1051–1055.
[PubMed]
https://doi.org/10.1016%2FS0140-6736%2895%2991739-X
8.
Abe H, Yoshizawa K, Kitahara T, Aizawa R, Matsuoka M, Aizawa Y: Etiology of non-B non-C hepatocellular carcinoma in the eastern district of Tokyo. J Gastroenterol 2008;43:967–974.
[PubMed]
https://doi.org/10.1007%2Fs00535-008-2264-8
9.
Fattovich G, Stroffolini T, Zagni I, Donato F: Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004;127:S35–S50.
[PubMed]
https://doi.org/10.1053%2Fj.gastro.2004.09.014
10.
Hassan MM, Hwang LY, Hatten CJ, Swaim M, Li D, Abbruzzese JL, Beasley P, Patt YZ: Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology 2002;36:1206–1213.
[PubMed]
https://doi.org/10.1053%2Fjhep.2002.36780
11.
Kawaguchi T, Kakuma T, Yatsuhashi H, Watanabe H, Saitsu H, Nakao K, Taketomi A, Ohta S, Tabaru A, Takenaka K, Mizuta T, Nagata K, Komorizono Y, Fukuizumi K, Seike M, Matsumoto S, Maeshiro T, Tsubouchi H, Muro T, Inoue O, Akahoshi M, Sata M: Data mining reveals complex interactions of risk factors and clinical feature profiling associated with the staging of non-hepatitis B virus/non-hepatitis C virus-related hepatocellular carcinoma. Hepatol Res 2011;41:564–571.
[PubMed]
https://doi.org/10.1111%2Fj.1872-034X.2011.00799.x
12.
Hashimoto E, Taniai M, Kaneda H, Tokushige K, Hasegawa K, Okuda H, Shiratori K, Takasaki K: Comparison of hepatocellular carcinoma patients with alcoholic liver disease and nonalcoholic steatohepatitis. Alcohol Clin Exp Res 2004;28:164S–168S.
[PubMed]
https://doi.org/10.1111%2Fj.1530-0277.2004.tb03237.x
13.
Honda H, Ochiai K, Adachi E, Yasumori K, Hayashi T, Kawashima A, Fukuya T, Gibo M, Matsumata T, Tsuneyoshi M: Hepatocellular carcinoma: correlation of CT, angiographic, and histopathologic findings. Radiology 1993;189:857–862.
[PubMed]
14.
Hennes EM, Zeniya M, Czaja AJ, Parés A, Dalekos GN, Krawitt EL, Bittencourt PL, Porta G, Boberg KM, Hofer H, Bianchi FB, Shibata M, Schramm C, Eisenmann de Torres B, Galle PR, McFarlane I, Dienes HP, Lohse AW, Group IAH: Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 2008;48:169–176.
[PubMed]
https://doi.org/10.1002%2Fhep.22322
15.
Yamamoto K, Terada R, Okamoto R, Hiasa Y, Abe M, Onji M, Tsuji T: A scoring system for primary biliary cirrhosis and its application for variant forms of autoimmune liver disease. J Gastroenterol 2003;38:52–59.
[PubMed]
https://doi.org/10.1007%2Fs005350300006
16.
Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R: Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973;60:646–649.
[PubMed]
https://doi.org/10.1002%2Fbjs.1800600817
17.
Greene FL, Page D, Fleming ID, et al: AJCC Cancer Staging Manual, ed 6. Chicago, Springer, 2002.
18.
El-Serag HB, Tran T, Everhart JE: Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004;126:460–468.
[PubMed]
https://doi.org/10.1053%2Fj.gastro.2003.10.065
19.
Davila JA, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB: Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut 2005;54:533–539.
[PubMed]
https://doi.org/10.1136%2Fgut.2004.052167
20.
Morimoto A, Nishimura R, Tajima N: Trends in the epidemiology of patients with diabetes in Japan. JMAJ 2010;53:36–40.
21.
Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, McCullough AJ, Natale S, Forlani G, Melchionda N: Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001;50:1844–1850.
[PubMed]
https://doi.org/10.2337%2Fdiabetes.50.8.1844
22.
Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, Natale S, Vanni E, Villanova N, Melchionda N, Rizzetto M: Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003;37:917–923.
[PubMed]
https://doi.org/10.1053%2Fjhep.2003.50161
23.
Ekstedt M, Franzén LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, Kechagias S: Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006;44:865–873.
[PubMed]
https://doi.org/10.1002%2Fhep.21327
24.
Ascha MS, Hanouneh IA, Lopez R, Tamimi TA, Feldstein AF, Zein NN: The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 2010;51:1972–1978.
[PubMed]
https://doi.org/10.1002%2Fhep.23527
25.
Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ: Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999;116:1413–1419.
[PubMed]
https://doi.org/10.1016%2FS0016-5085%2899%2970506-8
26.
Poonawala A, Nair SP, Thuluvath PJ: Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study. Hepatology 2000;32:689–692.
[PubMed]
https://doi.org/10.1053%2Fjhep.2000.17894
27.
El-Serag HB, Rudolph KL: Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007;132:2557–2576.
[PubMed]
https://doi.org/10.1053%2Fj.gastro.2007.04.061
© 2011 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2011
You do not currently have access to this content.